For a nice list of monoclonal antibodies currently on the market see (Shukla, “Recent advances in large-scale production of monoclonal antibodies and related proteins” Trends in Biotechnology, 28(5) pp. 253-261)

IL-1:

Anakinra targets the effects of IL-1 by competing with IL-1 for the Il-1 receptor. 

–IL-1alpha: Hsieh (US  8,383,778) discloses anti-IL-1alpha antibodies for treating diseases. 

 IL-6:

Rajpal (US 13/857,867) discloses generating human monoclonal antibodies to human IL-6 using human Ig transgenic mouse strains which express human antibodies that are indistinguishable from antibodies isolated form humans (see also monoclonal antibody production on the right).

Tocilizumab targets the IL-6 receptor. 

TNF-alpha:

–Infliximab is a chimeric anti TNF-alpha mAb.

 The EMA has approved Resmisma (or Inflectra), a biosimilar or originator infliximab (Remicade).

–adalimumab 

In the early 19902, Cambridge Antibody Technology Limited (CAT) and Knoll AG (“knoll”) (CAT changed its name to MedImmune Limited in 2007) begain a collaboration to develop therapeutic human antibodies and, in 1995, entered intoa Development and License Agreement. The collaboration led to the antibody adalimumab, the active ingredient of Humira. Uner the 1995 agreement, knoll recivd a license from CAT to certain patents including US 6,248,516 and US 7,306,907 and agreed to pay royalties on sales of certain antibodies reulting form the collaboration, including Humira. Abbvie (a spin off of Abbott Laboratories) is Knoll’s  successor in interest under the 1995 Agreemnt. 

Adalimumab binds to TNF-alpha and inhibits its interaction with cell surface receptors. Adalimumab refers to a FDA approved fully humanized IgG1 TNF alpha inhibitor monoclonal antibody (tradename Humira). Each IgG antibody molecule comprises two kappa light chains and two human IgG1 heavy chains, with a total MW of 148 kDa. Each light chain consists of 214 amino acids and each heavy chain consists of 451 amino acid residues. Adalimumab was derived form murine monoclonal antibody MAK195 using guided selection phage display and is produced in CHO cells. Physico-chemical studies reveal that adalimumab is present in three major fomrs, corresponding to molecules carrying two, one or no C terminal lysine. (Nti-Gyabaah, US 14/355014).

Adalimumab was approved by the FDA in 2002 and the European Agenecy for teh Evaluation of Medical (EMEA) products in 2003 for the treatment of rheumatoid arthritis. It was subsequently approved for the treatment of other TNF mediated chronic inflammatory diseases including psoriatic arthritis, chronic plaque psoriasis, ankylosing spondylitis, Crohn’s disease and polyarticular juvenile idiopathic arthritis. It can be used alone or in combination with methotrexate (MTX) or other nonbiological disease modifying anti-rheumatic drugs (DMARDs. For the treatment of RA, adlaimumab is typically administered by subcutaneous infection at 40 mg every one or two weeks. It is marketed in prefilled syringes and as an autoinjeciton device called HUMIRA Pen, which is typically used by patients for self administration. The prefilled syringes and autoinjector comprise 40 mg of adalimumab in 0.8 ml of a buffered solution of mannitol, citric aci monohydrate, sodium citrate, disodium phosphate dehydrate, sodium chloride and poysorbate 80.  (Nti-Gyabaah, US 14/355014)

— etarnercept is a TNF alpha receptor fusion protein.